{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T11:36:33Z","timestamp":1771932993759,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ygyno.2021.03.010","type":"journal-article","created":{"date-parts":[[2021,3,13]],"date-time":"2021-03-13T17:12:08Z","timestamp":1615655528000},"page":"203-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation"],"prefix":"10.1016","volume":"162","author":[{"given":"Bradley J.","family":"Monk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie M.","family":"Randall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian M.","family":"Slomovitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramez","family":"Eskander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavana","family":"Pothuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura L.","family":"Reese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Mannel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry J.","family":"Copeland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ygyno.2021.03.010_bb0025","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ygyno.2019.04.677","article-title":"European network of Gynaecological oncological trial groups (ENGOT); GOG foundation Inc. joint ENGOT and GOG foundation requirements for trials with industry partners","volume":"154","author":"Vergote","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.03.010_bb0035","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ygyno.2013.11.008","article-title":"Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper","volume":"132","author":"Herzog","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.03.010_bb0040","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2017.08.012","article-title":"Coleman RL.FDA ovarian cancer clinical trial endpoints workshop: a society of gynecologic oncology white paper","volume":"147","author":"Herzog","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.03.010_bb0045","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ygyno.2018.06.023","article-title":"Twenty-first century cervical cancer management: a historical perspective of the gynecologic oncology group\/NRG oncology over the past twenty years","volume":"150","author":"Leath","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2021.03.010_bb0050","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ygyno.2019.02.020","article-title":"Shaping the standard of care in ovarian cancer management: a review of gynecologic oncology group (GOG)\/NRG oncology clinical trials of the past twenty years","volume":"153","author":"DiSilvestro","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2021.03.010_bb0055","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ygyno.2017.11.026","article-title":"Clinical trials in gynecologic oncology: past, present, and future","volume":"148","author":"Annunziata","year":"2018","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2021.03.010_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"28","key":"10.1016\/j.ygyno.2021.03.010_bb0065","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","article-title":"Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study","volume":"27","author":"Monk","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"33","key":"10.1016\/j.ygyno.2021.03.010_bb0070","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.20.01076","article-title":"Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG oncology\/GOG0209)","volume":"38","author":"Miller","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.ygyno.2021.03.010_bb0075","doi-asserted-by":"crossref","first-page":"4626","DOI":"10.1200\/JCO.2005.10.021","article-title":"Fiorica JV; gynecologic oncology group study. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a gynecologic oncology group study","volume":"23","author":"Long","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2021.03.010_bb0080","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"10103","key":"10.1016\/j.ygyno.2021.03.010_bb0085","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.ygyno.2021.03.010_bb0090","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Liang SX; gynecologic oncology group. Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.ygyno.2021.03.010_bb0095","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.ygyno.2021.03.010_bb0100","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821002304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821002304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:55:02Z","timestamp":1758772502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821002304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0090825821002304"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.03.010","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The GOG partners: A program for industry sponsored clinical trials in gynecologic oncology within the GOG foundation","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}